ADAG
ACHAT TOTAL: 23245 titres (~84764 USD)
- Insiders
- Luo Peter
- Total bought
- $84,764
- Total sold
- —
- Last activity
- 2026-08-05
- Last synced
-
2026-08-09 12:58:10
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-09
ADAG's insider cluster buy and ADG126 trial progress generate a credible catalyst signal (score 70, confidence 0.65), but this is materially undermined by severely distressed fundamentals — negative operating margins…
The first sentence of the analysis written for ADAG on 2026-08-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | -797.5% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -227.4% | -31578.0% | -89.2% | -848.2% | -698.9% | |
| Ebitda Margin | -219.7% | -30680.5% | -82.5% | -832.8% | -687.8% | |
| Operating Profit Margin | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% | |
| Pretax Profit Margin | -233.4% | -32403.5% | -95.3% | -855.6% | -702.5% | |
| Continuous Operations Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Net Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Bottom Line Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.5% | |
| Current Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Quick Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Solvency Ratio | -0.397 | -0.839 | -0.393 | -1.133 | -2.187 | |
| Cash Ratio | 2.961 | 2.231 | 3.495 | 2.610 | 5.848 | |
| Price To Earnings Ratio | -4.086 | -2.095 | -3.509 | -0.573 | -3.527 | |
| Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Forward Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Price To Earnings Diluted Ratio | -4.086 | -2.095 | -3.591 | -0.573 | -3.527 | |
| Price To Earnings Diluted Growth Ratio | 0.080 | -0.027 | 0.047 | -0.524 | -0.012 | |
| Price To Book Ratio | 2.019 | 1.419 | 0.948 | 0.552 | 1.650 | |
| Price To Sales Ratio | 9.304 | 694.627 | 3.692 | 4.940 | 25.390 | |
| Price To Free Cash Flow Ratio | -4.553 | -2.411 | -2.343 | -0.931 | -5.626 | |
| Price To Operating Cash Flow Ratio | -4.558 | -2.414 | -2.350 | -0.944 | -5.951 | |
| Debt To Assets Ratio | 0.080 | 0.207 | 0.193 | 0.184 | 0.040 | |
| Debt To Equity Ratio | 0.177 | 0.366 | 0.316 | 0.337 | 0.048 | |
| Debt To Capital Ratio | 0.151 | 0.268 | 0.240 | 0.252 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.031 | 0.008 | 0.161 | 0.145 | 0.019 | |
| Financial Leverage Ratio | 2.214 | 1.767 | 1.640 | 1.834 | 1.210 | |
| Working Capital Turnover Ratio | 0.151 | 0.002 | 0.206 | 0.074 | 0.093 | |
| Operating Cash Flow Ratio | -0.622 | -0.778 | -0.905 | -0.883 | -1.456 | |
| Operating Cash Flow Sales Ratio | -2.041 | -287.789 | -1.571 | -5.231 | -4.267 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 1.003 | 1.014 | 1.058 | |
| Debt Service Coverage Ratio | -3.042 | -1.697 | -1.751 | -5.439 | -14.747 | |
| Interest Coverage Ratio | -46.290 | -42.203 | -21.411 | -121.041 | -198.933 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | -1.669 | -3.389 | -3.569 | -9.653 | |
| Operating Cash Flow Coverage Ratio | -2.500 | -1.606 | -1.276 | -1.738 | -5.797 | |
| Capital Expenditure Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Paid And Capex Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.185 | -0.158 | 1.389 | 0.903 | -1.307 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲897.5% | ▲179.5% |
| Ebit Margin | -227.4% | ▲31350.6% | ▲6460.9% |
| Ebitda Margin | -219.7% | ▲30460.8% | ▲6281.0% |
| Operating Profit Margin | -279.5% | ▲34555.9% | ▲7092.6% |
| Pretax Profit Margin | -233.4% | ▲32170.0% | ▲6624.6% |
| Continuous Operations Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Net Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Bottom Line Profit Margin | -229.6% | ▲32156.9% | ▲6630.6% |
| Current Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Quick Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Solvency Ratio | -0.397 | ▲0.442 | ▲0.593 |
| Cash Ratio | 2.961 | ▲0.730 | ▼-0.468 |
| Price To Earnings Ratio | -4.087 | ▼-1.992 | ▼-1.328 |
| Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Forward Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Price To Earnings Diluted Ratio | -4.087 | ▼-1.992 | ▼-1.312 |
| Price To Earnings Diluted Growth Ratio | 0.080 | ▲0.107 | ▲0.167 |
| Price To Book Ratio | 2.019 | ▲0.600 | ▲0.701 |
| Price To Sales Ratio | 9.305 | ▼-685.322 | ▼-138.286 |
| Price To Free Cash Flow Ratio | -4.553 | ▼-2.143 | ▼-1.381 |
| Price To Operating Cash Flow Ratio | -4.559 | ▼-2.145 | ▼-1.315 |
| Debt To Assets Ratio | 0.080 | ▼-0.127 | ▼-0.061 |
| Debt To Equity Ratio | 0.177 | ▼-0.189 | ▼-0.072 |
| Debt To Capital Ratio | 0.150 | ▼-0.117 | ▼-0.041 |
| Long Term Debt To Capital Ratio | 0.031 | ▲0.023 | ▼-0.042 |
| Financial Leverage Ratio | 2.214 | ▲0.447 | ▲0.481 |
| Working Capital Turnover Ratio | 0.151 | ▲0.149 | ▲0.046 |
| Operating Cash Flow Ratio | -0.622 | ▲0.156 | ▲0.306 |
| Operating Cash Flow Sales Ratio | -2.041 | ▲285.748 | ▲58.139 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | -0.000 | ▼-0.014 |
| Debt Service Coverage Ratio | -3.042 | ▼-1.345 | ▲2.293 |
| Interest Coverage Ratio | -46.290 | ▼-4.087 | ▲39.686 |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | ▼-1.475 | ▲1.141 |
| Operating Cash Flow Coverage Ratio | -2.500 | ▼-0.894 | ▲0.083 |
| Capital Expenditure Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Paid And Capex Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.185 | ▼-0.027 | ▼-0.313 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $71.4M | $71.7M | $66.9M | $45.9M | $258.4M | |
| Enterprise value | $3.1M | $5.0M | -$20.8M | -$69.9M | $91.5M | |
| EV / Sales | 0.41x | 48.33x | -1.15x | -7.52x | 8.99x | |
| EV / Op. cash flow | -0.20x | -0.17x | 0.73x | 1.44x | -2.11x | |
| EV / Free cash flow | -0.20x | -0.17x | 0.73x | 1.42x | -1.99x | |
| EV / EBITDA | -0.18x | -0.16x | 1.39x | 0.90x | -1.31x | |
| Net debt / EBITDA | 4.05x | 2.11x | 5.86x | 1.50x | 2.38x | |
| Current ratio | 3.07x | 2.30x | 3.61x | 2.71x | 6.24x | |
| Income quality | 0.89x | 0.89x | 1.50x | 0.61x | 0.59x | |
| Graham net-net | $1 | $1 | $2 | $2 | $5 | |
| Tax burden | 98.3% | 99.9% | 109.8% | 100.6% | 102.4% | |
| Interest burden | 102.7% | 102.6% | 106.9% | 100.9% | 100.5% | |
| Working capital | $52.2M | $49.6M | $82.0M | $94.2M | $156.1M | |
| Invested capital | $53.1M | $51.0M | $84.2M | $97.2M | $159.6M | |
| Return on assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Operating ROA | -25.6% | -35.1% | -17.7% | -49.1% | -52.9% | |
| Return on tangible assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Return on equity | -49.8% | -66.2% | -26.9% | -96.2% | -46.7% | |
| Return on invested capital | -36.2% | -52.0% | -25.5% | -75.5% | -44.1% | |
| Return on capital employed | -40.4% | -70.4% | -28.1% | -86.2% | -45.3% | |
| Earnings yield | -24.7% | -46.6% | -28.3% | -174.2% | -28.3% | |
| Free cash flow yield | -22.0% | -41.5% | -42.7% | -107.4% | -17.8% | |
| Capex / Op. cash flow | -0.1% | -0.1% | -0.3% | -1.4% | -5.8% | |
| Capex / Depreciation | 2.9% | 3.6% | 7.0% | 47.7% | 223.1% | |
| Capex / Sales | 0.2% | 32.5% | 0.5% | 7.4% | 24.7% | |
| SG&A / Sales | 92.2% | 7047.5% | 47.9% | 127.8% | 141.9% | |
| R&D / Sales | 287.2% | 27887.9% | 202.3% | 875.3% | 669.3% | |
| Stock comp / Sales | 48.8% | 4757.2% | 40.1% | 113.2% | 183.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 1d | 29d | 4d | 24d | 269d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 1d | 29d | 4d | 24d | 269d | |
| Cash conversion cycle | 1d | 29d | 4d | 24d | 269d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-0.4%EV / Sales ▼-99.2%EV / EBITDA ▼-17.3%EV / Op. cash flow ▼-0.031Earnings yield ▲+0.220
Profitability
Return on equity ▲+0.163Return on assets ▲+0.149Return on invested capital ▲+0.158Return on capital employed ▲+0.300Operating ROA ▲+0.095Income quality ▲+0.001Tax burden ▼-0.016
Efficiency
Days sales outstanding ▼-28.561Days payables outstanding n/aOperating cycle ▼-28.561Cash conversion cycle ▼-28.561Capex / Sales ▼-0.323R&D / Sales ▼-276.006
Balance-sheet strength
Current ratio ▲+0.775Net debt / EBITDA ▲+1.943Working capital ▲+2610002.000Invested capital ▲+2063877.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-72.4%EV / Sales ▼-95.5%EV / EBITDA ▲+85.9%EV / Op. cash flow ▲+1.908Earnings yield ▲+0.037
Profitability
Return on equity ▼-0.031Return on assets ▲+0.161Return on invested capital ▲+0.078Return on capital employed ▲+0.049Operating ROA ▲+0.273Income quality ▲+0.296Tax burden ▼-0.040
Efficiency
Days sales outstanding ▼-268.449Days payables outstanding n/aOperating cycle ▼-268.449Cash conversion cycle ▼-268.449Capex / Sales ▼-0.244R&D / Sales ▼-3.820
Balance-sheet strength
Current ratio ▼-3.162Net debt / EBITDA ▲+1.665Working capital ▼-103928851.000Invested capital ▼-106553559.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-06-05 Adagene (ADAG) Upgraded to Buy: Here''s What You Should Know Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-06-02 Are Medical Stocks Lagging Adagene (ADAG) This Year? Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
- 2026-05-19 Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company''s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company''s focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
- 2026-05-12 Adagene to Participate in Two Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.